KR20240097839A - LpxC 억제제 및 이의 용도 - Google Patents
LpxC 억제제 및 이의 용도 Download PDFInfo
- Publication number
- KR20240097839A KR20240097839A KR1020247013555A KR20247013555A KR20240097839A KR 20240097839 A KR20240097839 A KR 20240097839A KR 1020247013555 A KR1020247013555 A KR 1020247013555A KR 20247013555 A KR20247013555 A KR 20247013555A KR 20240097839 A KR20240097839 A KR 20240097839A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutically acceptable
- compound
- alkyl
- acceptable salt
- independently hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163249166P | 2021-09-28 | 2021-09-28 | |
| US63/249,166 | 2021-09-28 | ||
| PCT/US2022/044710 WO2023055686A1 (en) | 2021-09-28 | 2022-09-26 | Lpxc inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240097839A true KR20240097839A (ko) | 2024-06-27 |
Family
ID=85783440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247013555A Pending KR20240097839A (ko) | 2021-09-28 | 2022-09-26 | LpxC 억제제 및 이의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12187754B2 (https=) |
| EP (1) | EP4408853A4 (https=) |
| JP (1) | JP2024536864A (https=) |
| KR (1) | KR20240097839A (https=) |
| CN (1) | CN118302429A (https=) |
| AR (1) | AR127139A1 (https=) |
| AU (1) | AU2022357226A1 (https=) |
| CA (1) | CA3233328A1 (https=) |
| IL (1) | IL311588A (https=) |
| MX (1) | MX2024003859A (https=) |
| TW (1) | TW202322818A (https=) |
| WO (1) | WO2023055686A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019345150A1 (en) * | 2018-09-20 | 2021-05-13 | Blacksmith Medicines, Inc. | Antibacterial compounds |
| TW202322818A (zh) | 2021-09-28 | 2023-06-16 | 美商福吉醫療公司 | Lpxc抑制劑及其用途 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US5543534A (en) | 1994-12-29 | 1996-08-06 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US6699849B1 (en) | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
| US6875619B2 (en) | 1999-11-12 | 2005-04-05 | Motorola, Inc. | Microfluidic devices comprising biochannels |
| US20050009101A1 (en) | 2001-05-17 | 2005-01-13 | Motorola, Inc. | Microfluidic devices comprising biochannels |
| ES2572030T3 (es) | 2001-08-10 | 2017-07-19 | Shionogi & Co., Ltd. | Agente antiviral |
| AR037641A1 (es) | 2001-12-05 | 2004-11-17 | Tularik Inc | Moduladores de inflamacion |
| WO2003063831A2 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Immediate release dosage forms containing solid drug dispersions |
| KR101076018B1 (ko) | 2003-01-08 | 2011-10-21 | 유니버시티 오브 워싱톤 | 항균제 |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| WO2005110399A2 (en) | 2004-04-29 | 2005-11-24 | The Regents Of The University Of California | Zinc-binding groups for metalloprotein inhibitors |
| WO2006028523A2 (en) | 2004-04-29 | 2006-03-16 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO USDC Technology Transfer Office | Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
| WO2008027466A1 (en) | 2006-08-31 | 2008-03-06 | Schering Corporation | Hydantoin derivatives useful as antibacterial agents |
| BRPI0720547A2 (pt) | 2006-10-05 | 2014-05-06 | Janssen Pharmaceutica Nv | Inibidores de metaloprotease derivada de heterocíclico |
| TWI519508B (zh) | 2007-06-12 | 2016-02-01 | Achaogen Inc | 抗菌劑 |
| US8871728B2 (en) | 2007-06-29 | 2014-10-28 | Georgia Tech Research Corporation | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof |
| WO2010059838A2 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects |
| IT1392249B1 (it) | 2008-11-28 | 2012-02-22 | Univ Degli Studi Urbino | Derivati di [(3-idrossi-4-piron-2-il)metil]-amina e loro uso come farmaci anti-neoplastici |
| WO2010100475A1 (en) | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
| AU2012273100B2 (en) | 2011-06-19 | 2017-05-25 | Viamet Pharmaceuticals (NC), Inc. | Metalloenzyme inhibitor compounds |
| US9394260B2 (en) | 2012-04-03 | 2016-07-19 | Bristol-Myers Squibb Company | Pyrimidinone carboxamide inhibitors of endothelial lipase |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| KR20150039832A (ko) | 2012-08-06 | 2015-04-13 | 사피라 파르마슈티칼즈 게엠베하 | 디하이드록시피리미딘 탄산 유도체 및 바이러스성 질환의 치료, 개선 또는 예방에서의 이의 용도 |
| AU2014209107B2 (en) | 2013-01-28 | 2018-04-12 | Viamet Pharmaceuticals (NC), Inc. | Metalloenzyme inhibitor compounds |
| WO2014160649A1 (en) | 2013-03-29 | 2014-10-02 | Novartis Ag | Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections |
| US10647664B2 (en) | 2013-08-16 | 2020-05-12 | Duke University | Substituted hydroxamic acid compounds |
| WO2015085238A1 (en) | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibitors of lpxc |
| WO2015099107A1 (ja) | 2013-12-26 | 2015-07-02 | 塩野義製薬株式会社 | 含窒素６員環誘導体およびそれらを含有する医薬組成物 |
| BR112017004798A2 (pt) | 2014-09-12 | 2017-12-12 | Toyama Chemical Co Ltd | composição farmacêutica que contém um derivado de ácido hidroxâmico ou um seu sal |
| DK3233843T3 (da) * | 2014-12-16 | 2019-11-18 | Novartis Ag | Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere |
| CN105777464B (zh) | 2014-12-26 | 2020-09-29 | 中国科学院上海药物研究所 | 异羟肟酸衍生物及其制备方法和应用 |
| WO2017083434A1 (en) | 2015-11-09 | 2017-05-18 | Forge Therapeutics, Inc. | Pyrone based compounds for treating bacterial infections |
| EP3374350B1 (en) | 2015-11-09 | 2022-01-05 | Forge Therapeutics, Inc. | Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections |
| CN105669750B (zh) * | 2016-03-01 | 2018-04-03 | 中国医学科学院医药生物技术研究所 | 新型锌离子螯合剂及其制备和在抗革兰氏阴性菌感染中的应用 |
| US10889556B2 (en) | 2016-03-08 | 2021-01-12 | The Regents Of The University Of California | Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease |
| MX388647B (es) | 2016-12-23 | 2025-03-20 | Intervet Int Bv | Compuestos utiles para el tratamiento de una infeccion por mannheimia haemolytica o histophilus somni. |
| JPWO2018143162A1 (ja) * | 2017-01-31 | 2019-11-14 | 富士フイルム富山化学株式会社 | ヒドロキサム酸のプロドラッグである化合物またはその塩、凍結乾燥製剤、ＬｐｘＣ阻害剤および抗菌剤 |
| WO2018208987A2 (en) | 2017-05-10 | 2018-11-15 | Forge Therapeutics, Inc. | Antibacterial compounds |
| US11021471B2 (en) | 2017-05-10 | 2021-06-01 | Forge Therapeutics, Inc. | Antibacterial compounds |
| WO2019086452A1 (en) | 2017-10-31 | 2019-05-09 | Idorsia Pharmaceuticals Ltd | Antibacterial heteroaromatic compounds |
| BR112020016270A2 (pt) | 2018-02-10 | 2020-12-15 | Kbp Biosciences Co., Ltd. | Composto atuando como antibióticos |
| AU2019345150A1 (en) | 2018-09-20 | 2021-05-13 | Blacksmith Medicines, Inc. | Antibacterial compounds |
| WO2020102572A1 (en) | 2018-11-14 | 2020-05-22 | Forge Therapeutics, Inc. | Antibacterial compounds |
| WO2021195258A1 (en) | 2020-03-25 | 2021-09-30 | Forge Therapeutics, Inc. | Lpxc inhibitor, formulations, and uses thereof |
| WO2021195260A1 (en) | 2020-03-25 | 2021-09-30 | Forge Therapeutics, Inc. | Lpxc inhibitor and methods of making |
| WO2022086920A1 (en) | 2020-10-20 | 2022-04-28 | Blacksmith Medicines, Inc. | Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof |
| EP4291550A4 (en) | 2021-02-11 | 2025-01-22 | Blacksmith Medicines, Inc. | Antibacterial compounds |
| TW202322818A (zh) | 2021-09-28 | 2023-06-16 | 美商福吉醫療公司 | Lpxc抑制劑及其用途 |
| TW202417432A (zh) | 2022-08-10 | 2024-05-01 | 美商布萊克史密斯醫藥公司 | 抗菌化合物 |
| WO2024036170A1 (en) | 2022-08-10 | 2024-02-15 | Blacksmith Medicines, Inc. | Antibacterial compounds |
-
2022
- 2022-09-26 TW TW111136418A patent/TW202322818A/zh unknown
- 2022-09-26 IL IL311588A patent/IL311588A/en unknown
- 2022-09-26 MX MX2024003859A patent/MX2024003859A/es unknown
- 2022-09-26 WO PCT/US2022/044710 patent/WO2023055686A1/en not_active Ceased
- 2022-09-26 AR ARP220102572A patent/AR127139A1/es not_active Application Discontinuation
- 2022-09-26 CN CN202280077994.XA patent/CN118302429A/zh active Pending
- 2022-09-26 KR KR1020247013555A patent/KR20240097839A/ko active Pending
- 2022-09-26 JP JP2024518830A patent/JP2024536864A/ja active Pending
- 2022-09-26 EP EP22877185.3A patent/EP4408853A4/en active Pending
- 2022-09-26 CA CA3233328A patent/CA3233328A1/en active Pending
- 2022-09-26 AU AU2022357226A patent/AU2022357226A1/en active Pending
-
2024
- 2024-03-26 US US18/616,636 patent/US12187754B2/en active Active
- 2024-11-25 US US18/958,407 patent/US20250230180A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022357226A1 (en) | 2024-05-02 |
| JP2024536864A (ja) | 2024-10-08 |
| MX2024003859A (es) | 2024-05-21 |
| US20250230180A1 (en) | 2025-07-17 |
| IL311588A (en) | 2024-05-01 |
| US12187754B2 (en) | 2025-01-07 |
| TW202322818A (zh) | 2023-06-16 |
| US20240270773A1 (en) | 2024-08-15 |
| EP4408853A4 (en) | 2025-08-27 |
| WO2023055686A1 (en) | 2023-04-06 |
| AR127139A1 (es) | 2023-12-20 |
| CA3233328A1 (en) | 2023-04-06 |
| CN118302429A (zh) | 2024-07-05 |
| EP4408853A1 (en) | 2024-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250230180A1 (en) | Lpxc inhibitors and uses thereof | |
| EP3517538B1 (en) | Pyrazolopyridine derivative having glp-1 receptor agonist effect | |
| EP2721026A1 (en) | Phosphate esters of gyrase and topoisomerase inhibitors | |
| US20240002373A1 (en) | Lpxc inhibitor and methods of making | |
| TW201925201A (zh) | 二氮雜二環辛烷衍生物 | |
| JP2024507139A (ja) | 抗菌性化合物 | |
| JP2025526728A (ja) | 抗菌化合物 | |
| TW202302119A (zh) | 作為β－內醯胺酶抑制劑的硼酸衍生物 | |
| WO2020163479A1 (en) | Antibiotic ammonium compounds and methods for the treatment of bacterial infections | |
| RU2680138C2 (ru) | Трициклические ингибиторы гиразы | |
| EP4406962A1 (en) | Macrocyclic peptidomimetic protease inhibitor and use thereof | |
| JPWO1998002431A1 (ja) | シス置換アミノシクロプロパン誘導体 | |
| EP0990654B1 (en) | Substituted cyclobutylamine derivatives | |
| EP0924213B1 (en) | Pyridobenzoxazine derivatives | |
| US20230227482A1 (en) | Tetrahydrocannabinol derivatives, preparation method thereof and use thereof | |
| KR102680438B1 (ko) | 콘테졸리드 아세포사밀의 약물 결정 및 이의 제조 방법 및 응용 | |
| WO2018081858A1 (en) | Improved analogues of desferrioxamine b and their uses | |
| WO2025078209A1 (en) | Antibiotic compounds for treating bacterial infections | |
| US20250312362A1 (en) | INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | |
| EA049173B1 (ru) | ПРОИЗВОДНОЕ БОРНОЙ КИСЛОТЫ, ДЕЙСТВУЮЩЕЕ В КАЧЕСТВЕ ИНГИБИТОРА β-ЛАКТАМАЗ | |
| HK1025964A (en) | Substituted cyclobutylamine derivatives | |
| NO315939B1 (no) | N1-(halogencyklopropyl)-substituert pyridonkarboksylsyrederivat, antibakterielt preparat omfattende en slik forbindelse, anvendelse avforbindelsensamt fremgangsmåte for fremstilling derav | |
| BR122021023465B1 (pt) | Derivado de pirazolopiridina, seu uso e composição farmacêutica | |
| BR112019005322B1 (pt) | Derivado de pirazolopiridina e seu sal de cálcio hemi-hidratado, composição farmacêutica e seu uso | |
| MXPA99011056A (en) | Substituted cyclobutylamine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |